In the International AMD Genomics Consortium (IAMDGC), we gathered 26 studies with each including (i) advanced AMD cases with GA and/or CNV in at least one eye and age at first diagnosis ≥ 50 years, (ii) intermediate AMD cases with pigmentary changes in the RPE or more than five macular drusen greater than 63μm and age at first diagnosis ≥ 50 years, or (iii) controls without known advanced or intermediate AMD. Recruitment and ascertainment strategies varied by study (Supplementary Tables 1 and 2, Supplementary Note 7). All groups collected data according to the Declaration of Helsinki principles. Study participants provided informed consent and protocols were reviewed and approved by local ethics committees.